Provided by Tiger Trade Technology Pte. Ltd.

crane

195.45
-3.8000-1.91%
Volume:367.10K
Turnover:72.19M
Market Cap:11.26B
PE:34.11
High:201.59
Open:200.73
Low:195.30
Close:199.25
52wk High:230.50
52wk Low:159.58
Shares:57.60M
Float Shares:48.76M
Volume Ratio:1.17
T/O Rate:0.75%
Dividend:0.98
Dividend Rate:0.50%
EPS(TTM):5.73
EPS(LYR):6.26
ROE:16.52%
ROA:12.73%
PB:5.17
PE(LYR):31.24

Loading ...

Crane reports Q2 adjusted EPS $1.79, consensus $1.67

TIPRANKS
·
Jul 29

Crane Company Q2 Sales USD 724.7 Million Vs. IBES Estimate USD 706.2 Million

Reuters
·
Jul 29

Crane Holdings Q2 Adj. EPS $1.63 Misses $1.67 Estimate, Sales $724.700M Beat $706.178M Estimate

Benzinga Earnings
·
Jul 29

Crane Co Fy2026 Shr View $6.82

THOMSON REUTERS
·
Jul 29

Crane Company Outlook FY Adjusted EPS USD 6.85-7.05 VS. Ibes Estimate USD 6.82

THOMSON REUTERS
·
Jul 29

Crane Company Reports Second Quarter 2026 Results and Raises Full Year Adjusted EPS Guidance

THOMSON REUTERS
·
Jul 29

U.S. Earnings Preview: After Market Close July 28

Dow Jones
·
Jul 29

Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Dow Jones
·
Jul 28

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 27

Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

Dow Jones
·
Jul 20

Crane (CR) Acquires PSI, Is The Stock Near Fair Value?

Simply Wall St.
·
Jul 20

Analysts Offer Insights on Industrial Goods Companies: ABB Ltd (OtherABBNY) and Crane Company (CR)

TIPRANKS
·
Jul 20

InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL

GlobeNewswire
·
Jul 14

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

GlobeNewswire
·
Jul 07

Crane (CR) Leaves Russell Defensive Indexes, Is The Premium Already Priced In?

Simply Wall St.
·
Jul 06

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

GlobeNewswire
·
Jun 30

Crane Updates Financial Calendar with Second-quarter 2026 Earnings Release, Teleconference Schedule

Reuters
·
Jun 29

Crane Company Announces Date for Second Quarter 2026 Earnings Release and Teleconference

THOMSON REUTERS
·
Jun 29

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

GlobeNewswire
·
Jun 14